Gefitinib (Iressa(®), ZD1839) is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. We report on an early cellular response to gefitinib that involves induction of functional autophagic flux in phenotypically diverse breast cancer cells that were sensitive (BT474 and SKBR3) or insensitive (MCF7-GFPLC3 and JIMT-1) to gefitinib. Our data show that elevation of autophagy in gefitinib-treated breast cancer cells correlated with downregulation of AKT and ERK1/2 signaling early in the course of treatment. Inhibition of autophagosome formation by BECLIN-1 or ATG7 siRNA in combination with gefitinib reduced the abundance of autophagic organelles and sensitized SKBR3 but not MCF7-GFPLC3 cells to cell death. Ho...
An increasing number of studies have emphasized the role of autophagy in cancer cell metastasis and ...
Resistance to EGFR-targeted therapy is a major obstacle on the road to effective treatment options f...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, are ef...
Gefitinib (Iressa®, ZD1839) is a small molecule inhibitor of the epidermal growth factor receptor (E...
<div><p>Gefitinib (Iressa<sup>®</sup>, ZD1839) is a small molecule inhibitor of the epidermal growth...
Gefitinib (Iressa®, ZD1839) is a small molecule inhibitor of the epidermal growth factor receptor (E...
Epidermal growth factor receptor (EGFR) is over-expressed in about 50% of Triple negative breast can...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, are ef...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, are ef...
The epidermal growth factor receptor (EGFR) signaling pathways are altered in many cancers contribut...
The epidermal growth factor receptor (EGFR) signaling pathway is frequently dysregulated in a variet...
Despite the potential therapeutic efficacy of epithelial growth factor receptor (EGFR) inhibitors in...
Despite the potential therapeutic efficacy of epithelial growth factor receptor (EGFR) inhibitors in...
Gefitinib, a smallmolecule inhibitor of the epidermal growth factor receptor tyrosine kinase, has be...
INTRODUCTION:Gefitinib (Iressa, ZD 1839, AstraZeneca) blocks the tyrosine kinase activity of the epi...
An increasing number of studies have emphasized the role of autophagy in cancer cell metastasis and ...
Resistance to EGFR-targeted therapy is a major obstacle on the road to effective treatment options f...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, are ef...
Gefitinib (Iressa®, ZD1839) is a small molecule inhibitor of the epidermal growth factor receptor (E...
<div><p>Gefitinib (Iressa<sup>®</sup>, ZD1839) is a small molecule inhibitor of the epidermal growth...
Gefitinib (Iressa®, ZD1839) is a small molecule inhibitor of the epidermal growth factor receptor (E...
Epidermal growth factor receptor (EGFR) is over-expressed in about 50% of Triple negative breast can...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, are ef...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, are ef...
The epidermal growth factor receptor (EGFR) signaling pathways are altered in many cancers contribut...
The epidermal growth factor receptor (EGFR) signaling pathway is frequently dysregulated in a variet...
Despite the potential therapeutic efficacy of epithelial growth factor receptor (EGFR) inhibitors in...
Despite the potential therapeutic efficacy of epithelial growth factor receptor (EGFR) inhibitors in...
Gefitinib, a smallmolecule inhibitor of the epidermal growth factor receptor tyrosine kinase, has be...
INTRODUCTION:Gefitinib (Iressa, ZD 1839, AstraZeneca) blocks the tyrosine kinase activity of the epi...
An increasing number of studies have emphasized the role of autophagy in cancer cell metastasis and ...
Resistance to EGFR-targeted therapy is a major obstacle on the road to effective treatment options f...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, are ef...